NervGen Pharma (NGENF) News Today $1.59 -0.04 (-2.45%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period NervGen Pharma Nears Trial Enrollment CompletionNovember 14, 2024 | markets.businessinsider.comHere's Why We're Not At All Concerned With NervGen Pharma's (CVE:NGEN) Cash Burn SituationAugust 18, 2024 | finance.yahoo.comEILMELDUNG: Riesige Wette gegen Omega könnte NACH HINTEN LOSGEHEN!August 3, 2024 | finanznachrichten.deNervGen Pharma Reports Q1 2024 Financial Results and Operational UpdatesMay 16, 2024 | finance.yahoo.comNervGen Pharma Corp. (NGENF)April 20, 2024 | finance.yahoo.comNervGen Pharma Reports 2023 Year-End Financial Results and Operational UpdatesApril 17, 2024 | finance.yahoo.comNervGen Completes $23 Million Bought Deal FinancingMarch 28, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - NGENMarch 22, 2024 | finance.yahoo.comNERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERINGMarch 21, 2024 | finance.yahoo.comNervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord InjuryFebruary 15, 2024 | finance.yahoo.comNervGen Pharma GAAP EPS of -$0.07November 9, 2023 | msn.comNeuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy KawasakiNovember 8, 2023 | finance.yahoo.comNervGen Pharma Corp Ordinary Shares NGENFNovember 4, 2023 | morningstar.comNervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord InjurySeptember 25, 2023 | finance.yahoo.comNervGen Pharma to Present at 2023 International Spinal Research Trust Network MeetingSeptember 11, 2023 | finance.yahoo.comNervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 5, 2023 | finance.yahoo.comNervGen Pharma to Present on its Drug Candidate NVG-291 and Spinal Cord Injury at Investor ConferenceAugust 22, 2023 | finance.yahoo.comNervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB ApprovalAugust 8, 2023 | finance.yahoo.comNervGen Pharma to Receive More than US$3 Million from Wings for Life to Support Upcoming Clinical Study in Spinal Cord InjuryJune 27, 2023 | finance.yahoo.comNervGen Pharma to Present at Upcoming Investor ConferencesJune 20, 2023 | finance.yahoo.comNervGen Pharma Corp.: NervGen Pharma Reports Q1 2023 Results and Provides Operational Update Including Clinical Trials of Proprietary NVG-291May 15, 2023 | finanznachrichten.deNervGen Pharma Reports Q1 2023 Results and Provides Operational Update Including Clinical Trials of Proprietary NVG-291May 15, 2023 | finance.yahoo.comRaleigh/Durham Pharmaceuticals NewsApril 14, 2023 | bizjournals.comNervGen Pharma Appoints Michael Kelly as President & Chief Executive OfficerApril 10, 2023 | finance.yahoo.comNervGen Pharma Reports 2022 Year End Results and Provides Operational Update Including Plans to Initiate Phase 1b/2a Clinical Trial of Proprietary NVG-291 in Q3 2023March 30, 2023 | finance.yahoo.comNervGen Pharma Corp. (NGEN.V)March 22, 2023 | ca.finance.yahoo.comNervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291February 14, 2023 | finance.yahoo.comNGEN:CA NervGen Pharma Corp.January 31, 2023 | seekingalpha.comNervGen Pharma Stock (OTC:NGENF), Quotes and News SummaryJanuary 10, 2023 | benzinga.comNervGen Pharma Announces Composition of Matter Patent for NVG-291 Granted by the US Patent and Trade OfficeNovember 17, 2022 | finance.yahoo.comNervGen Pharma Completes Dosing in Its Third Multiple Ascending Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q3 2022 ResultsNovember 14, 2022 | finance.yahoo.comNervGen Pharma Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291October 25, 2022 | finance.yahoo.comNervGen Pharma Announces Appointment of Dr. Matvey Lukashev as Vice President, Research and Preclinical DevelopmentSeptember 12, 2022 | finance.yahoo.comHas The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure?September 8, 2022 | finance.yahoo.comNervGen Pharma Presenting at Upcoming Military Health System Research Symposium and the 61st International Spinal Cord Society Annual Scientific MeetingSeptember 8, 2022 | finance.yahoo.comNervGen Pharma (NGENF) Investor Presentation - SlideshowAugust 14, 2022 | seekingalpha.comNervGen Pharma Reports Second Quarter 2022 Results and Provides Corporate UpdateAugust 10, 2022 | finance.yahoo.comNervGen Presenting Study Design for Upcoming Phase 1b/2a in Alzheimer's Disease at the 2022 Alzheimer's Association International ConferenceAugust 2, 2022 | finance.yahoo.comNervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve UniversityJuly 28, 2022 | finance.yahoo.comNervGen Pharma Closes US$15MM Private Placement and Appoints Dr. Adam Rogers to Board of DirectorsJuly 14, 2022 | finance.yahoo.comNervGen Pharma Provides Update on Closing of Private PlacementJuly 11, 2022 | finance.yahoo.comNervGen Pharma (OTC:NGENF), Short Interest ReportJuly 7, 2022 | benzinga.comNervGen Pharma Corp. Announces US$15MM Non-Brokered Private PlacementJune 30, 2022 | finance.yahoo.comNervGen Pharma Corp.: NervGen Pharma Grants Stock OptionsJune 2, 2022 | finanznachrichten.deNERVGEN PHARMA CORPMay 25, 2022 | finanznachrichten.deNervGen Hosting Panel Discussion with Leading Experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)May 16, 2022 | finance.yahoo.comNervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 ResultsMay 12, 2022 | finance.yahoo.comNervGen Presenting Interim Phase 1 Clinical Trial Data for NVG-291 at the 2022 American Academy of Neurology Annual MeetingMarch 31, 2022 | finance.yahoo.comNervGen Pharma to Present at 2022 Virtual Growth Conference Presented by Maxim GroupMarch 23, 2022 | finance.yahoo.comNervGen Pharma gets safety panel nod to advance in phase 1 trial of NVG-291March 15, 2022 | seekingalpha.com Get NervGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NGENF and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin NGENF Media Mentions By Week NGENF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NGENF News Sentiment▼0.000.47▲Average Medical News Sentiment NGENF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NGENF Articles This Week▼10▲NGENF Articles Average Week Get NervGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NGENF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CYBN News Today LIAN News Today IBIO News Today PHXM News Today BRTX News Today PHGE News Today NBY News Today AGNPF News Today AKBLF News Today DRTSW News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:NGENF) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NervGen Pharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share NervGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
